Literature DB >> 916087

Prostaglandin: increased production by renal cell carcinoma.

K B Cummings, R P Robertson.   

Abstract

The syndrome of hypercalcemia in patients with renal cell carcinoma without metastasis to bone, in association with elevated levels of immunoreactive prostaglandin E and normal parathyroid hormone levels, prompted the investigation of an etiologic relationship of increased prostaglandin in this syndrome. Ethyl acetate extracts of tissue culture effluents, primary and metastatic renal cell carcinoma, and plasma were chromatographed on silicic acid columns and assayed by double antibody immunoprecipitative methods for immunoprecipitative methods for immunoreactive prostaglandins A and E. Increased levels of immunoreactive prostaglandins A and E were found 1) to be generated in parallel with cell growth during a period of time by renal cell carcinoma in monolayer growth, 2) in extracts of primary and metastatic renal cell carcinoma tissue and 3) in the venous effluent of a kidney bearing a renal cell carcinoma. These findings support the hypothesis that renal cell carcinoma can produce prostaglandins. Furthermore, reported syndromes of patients with renal cell carcinoma associated with elevated prostaglandin levels may result from the autonomous production of prostaglandins in vivo by the tumor.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 916087     DOI: 10.1016/s0022-5347(17)58172-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Establishment and characterization of a new human renal cell carcinoma cell line (KRC/Y).

Authors:  H Yano; M Maruiwa; S Sugihara; M Kojiro; S Noda; K Eto
Journal:  In Vitro Cell Dev Biol       Date:  1988-01

2.  Role of endogenous prostaglandin E2 in erythropoietin production and dome formation by human renal carcinoma cells in culture.

Authors:  M Hagiwara; D B McNamara; I L Chen; J W Fisher
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

Review 3.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

4.  Human renal cell carcinoma: establishment and characterization of a new cell line (OS-RC-2).

Authors:  T Kinouchi; T Kotake; Y Mori; T Abe
Journal:  In Vitro Cell Dev Biol       Date:  1985-04

5.  Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction.

Authors:  D W Hoskin; T Reynolds; J Blay
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

Review 6.  Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature.

Authors:  Kara Pepper; Uraporn Jaowattana; Michael D Starsiak; Raghuueer Halkar; Kelly Hornaman; Wenli Wang; Priya Dayamani; Vin Tangpricha
Journal:  J Gen Intern Med       Date:  2007-04-19       Impact factor: 5.128

7.  Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations.

Authors:  S R Li; Q Yang; E Wandl; W Pirker; I Virgolini
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

8.  Modification of the carcinogenic process in colorectal cancer by endogenous and exogenous factors: effect of colestipol hydrochloride on tumors induced by dimethylhydrazine.

Authors:  J P Daugherty
Journal:  Environ Health Perspect       Date:  1983-04       Impact factor: 9.031

9.  Immune regulation of the L5178Y murine tumor-dormant state. I. In vivo and in vitro effects of prostaglandin E2 and indomethacin on tumor cell growth.

Authors:  C M Liu; T Okayasu; P Goldman; Y Suzuki; K Suzuki; E F Wheelock
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

10.  Peripheral plasma immunoreactive 6-oxo-prostaglandin F1 alpha and gynaecological tumours.

Authors:  M Alam; M Jogee; W G MacGregor; J W Dowdell; M G Elder; L Myatt
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.